100) McCarter FD, James JH, Luchette FA, Wang L, Friend LA, King JK, Evans JM, George MA, Fischer JE: Adrenergic blockade reduces skeletal muscle glycolysis and Na(+), K(+)-ATPase activity during hemorrhage. J Surg Res. 99: 235-44, 2001
101) James JH, F.A.Luchette, F.D.McFischer & J.E.Fischer (Cincinatti / USA): Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 354: 505-508, 1999
102) Luchette FA, Robinson BR, Friend LA, McCarter F, Frame SB, James JH (Cincinatti /USA): Adrenergic antagonists reduce lactic acidosis in response to hemorrhagic shock. J Trauma. 46: 873-80, 1999
103) Greenberger NJ, Richard P.MacDermott, James F.Martin & Saradindu Dutta (Chicago): Intestinal absorption of six tritium labeled digitalis glycosides in rats and guinea pigs. J Pharmacol Exp Ther 167: 265-273, 1969 (no abstract available in PubMed)
104) in german: Ohlmeier H & A.Ruiz-Torres: [Digitoxin and g-strophanthin absorption in the perfused small intestine loop of the rat]. Arzneim-Forsch 22 :1874-76, 1972
105) in german: Forth W, E.Furukawa, W.Rummel & H.Andres: [Determination of the intestinal absorption of cardiac glycosides by measurement of 3H-labelled glycosides in the portal venous blood and in the intestinal lymph of cats] Naunyn-Schmiedebergs Archiv 264 (1969) 406-419, 1969
106) in german: Forth W, E.Furukawa & W.Rummel: [Comparative studies of the absorption and elimination tritium-labelled cardiac glycosides] Naunyn-Schmiedebergs Arch Pharmak 263: 206-208, 1969
107) Marzo A, P.Ghirardi & G.Marchetti: The absorption, distribution and excretion of k-strophanthoside-3H in guinea- pigs afterparenteral administration. J Pharmacol Exp Ther 183: 185-193, 1974
108) Leuschner J& Winkler A (Hamburg): Toxicological studies with ouabain. Naunyn-Schmiedeberg´s Arch Pharmacol 363 Suppl.: 139, abstract 544, 2001(no abstract available in PubMed )
109) in german: Garbe A & H.Nowak: [On the pharmacokinetics of peruvoside. II. Comparative studies with H3-ouabain and H3-digitoxin in guinea pigs] Arzneimittel-Forsch 18: 1597-1601, 1968
110) in german: Forth W, E.Furukawa, W.Rummel & H.Andres: [Intestinal absorption of cardiac glycosides in vitro and in vivo] Naunyn-Schmiedebergs Arch Pharmak Exp Pathol 262: 53-72, 1969
111) in german: Forth W & W.Rummel: [Comparative study of intestinal resorption of 3H-labelled cardiac glycosides in vitro and in vivo] Naunyn-Schmiedebergs Archiv 260: 112-114, 1968
112) in german: Buchtela K, K.Drexler, A.Fehringer, H.Hackl, M.Königstein & J.Schläger: [Resorption, degradation and excretion of acetyldigoxin in animal experiments]. Wien Z Inn Med 51: 227-235, 1970
113) Kitano S, Shigeto Morimoto, Akira Nishibe, Keisuke Fukuo, Atushi Hirotani, Takeshi Nakahashi, Osamu Yasuda & Toshio Ogihara: Exogenous Ouabain is accumulated in the adrenals and mimics the kinetics of endogenous digitalis-like-factor in rats. Hypertens Res 21: 47-56, 1998
114) in german: Berthold Kern: Zum Nachweis der Strophanthin-Resorption. Medizinische Monatsschrift 6: 371-374, 1952
115) in german: Lendle L, W.Schwerbrock: Über die Wechselwirkungen von g-und k-Strophanthin... Arch Exp Path und Pharmakol 188: 317-327, 1938
116) in german: Fühner H: Rektale Strophanthin-Vergiftung. Der Fall Mertens-Dr.Richter. Dtsch Med Wschr 55: 1408-1409, 1929
117) abstract in english, text in german: Lauterbach F, Günther Vogel & Ingeborg Baumann: [Dependence of the intestinal efficiency rate of cardiac glycosides on the applied dose] Naunyn-Schmiedebergs Arch Pharmak exp Pathol 259: 248-259, 1968 (no abstract available in PubMed)
118) Lauterbach F in Kurt Greeff (ed.): "Handbook of Experimental Pharmacology", Vol. 56/II, 1981
119) Nunez-Duran H, Laura Riboni, Ernestina Ubaldo, Emilio Kabela, & Laura Barcenas-Ruiz: Ouabain uptake by endocytosis in isolated guinea pig atria. J Am Physiol 255: C479-C485, 1988
120) in german: Erdle HP, K.D.Schultz, E.Wetzel & F.Gross: Resorption und Ausscheidung von g-Strophanthin nach intravenöser und perlingualer Gabe. Dtsch Med Wschr. (Deutsche Medizinische Wochenschrift) 104: 976-979, 1979
121) Marchetti GV, A.Marzo, C.de Ponti, A.Scvalvini, L.Merlo & V.Noseda: Blood levels and tissue distribution of 3H-Ouabain administered per os, Arzneim Forsch (Drug Res) 21: 1399-1403, 1972
(no abstract available in PubMed)
122) Greeff K& K.E.Wirth: Pharmacokinetics of strophantus glykosides, in Kurt Greeff: Handbook of Experimental Pharmacology, Band 56 II : Cardiac Glykosides, S.56-85, Springer B-Hdlbg-N.Y., 1981
123) summary in english: Lahrtz H, R.W.Sattler & P.A.van Zwieten: [On the blood level and secretion of radioactively labeled cardiac glycosides following intraduodenal application in the cat] Z ges exp Med (Zeitschrift für die gesamte experimentelle Medizin) 148: 210-222, 1968 (no abstract available in PubMed)
124) in german: Greeff K, E.Köhler, H.Strobach, E.Verspohl: Zur Pharmakokinetik des g-Strophanthins. Verh Dtsch Ges Kreislaufforschg (Verhandlungen der Deutschen Gesellschaft für Kreislaufforschung) 40: 301-305, 1974
125) in german: Verspohl E: Entwicklung radioimmunologischer Methoden zur Bestimmung von Herzglykosiden des Digitoxigenins, g-Strophanthins und k-Strophantidins mit Untersuchungen zur Pharmakokinetik des Digitoxins und g-Strophanthins. Inaugural-Dissertation, Düsseldorf 1973
126) Strobach H, K.E.Wirth & K.Rojsathaporn: Absorption, metabolism and elimination of strophanthus glycosides in man. Naunyn-Schmiedebergs Arch Pharmacol 334: 496-500, 1986
127) Riehle M, J.Bereiter-Hahn & B.Boller (Frankfurt/M. / Germany): Effects of ouabain and digitoxin on the respiration of chick embryo cardiomyocytes in culture. Arzneim-Forsch / Drug Res 41: 378-384, 1991
127 a) Lopatina EV, Penniiaĭnen VA, Tsyrlin VA.: [Comparative analysis of the cardiac glycosides action on the growth of the cardiac tissue explants] article in Russian, abstract in English.
Ross Fiziol Zh Im I M Sechenova. 2005 91: 1299-304, 2005.
128) Hamlyn JM, M.P.Blaustein, S.Bova. D.W.DuCharme, D.W.Harris, F.Mandel, W.R.Mathews & J.H.Ludens (Baltimore / USA, Padua / Italy & Kalamazoo / USA): Identification and characterization of a ouabain-like compound from human plasma. Proc Nat Acad Sci USA 88: 259, 1991
129) Tymiak AA, Norman JA, Bolgar M, DiDonato GC, Lee H, Parker WL, Lo LC, Berova N, Nakanishi K, Haber E et al. (Princeton): Physiochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Nat Acad Sci USA 90:8189-8193, 1993
130) Zhao N, Lo LC, Berova N, Nakanishi K, Tymiak AA, Ludens JH, Haupert GT Jr. (New York): Na-K-ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: nanogram scale CD structural analysis. Biochemistry 34:9893-9896, 1995
131) Dong JG, Jinsong Guo, I.Akritopoulou-Zanze, Akira Kawamura, Koji Nakanishi & N.Berova (New York): Theoretical and experimental CD of conformationally flexible complex molecules: application to ouabain pentanaphtoate and analogs. Chirality, 11: 707-721, 1999
132) Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert GT Jr, Magil S, Gallagher RT, Berova N, Nakanishi K.(New York): On the structure of endogenous ouabain. Biochemistry 96:6654-6659, 1999
133) Schneider R, Wray V, Nimtz M, Lehmann WD, Kirch U, Antolovic R, Schoner W. (Giessen): Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J Biol Chem 273:784-792, 1998
134) Komiyama Y, Nishimura N, Dong XH, Hirose S, Kosaka C, Masaki H, Masuda M, Takahashi H (Morigucji / Japan): Liquid chromatography mass spectrometric analysis of ouabainlike factor in biological fluid. Hypertens Res 23 (Suppl):S21-S27, 2000
135) Hamlyn, John M., James Laredo, Jui R. Shah, Zhuo Ren Lu & Bruce P.Hamilton : 11-Hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann N.Y. Acad Sci 986 : 685-693, 2003
136) Kramer HJ, Krampitz G, Backer A, Meyer-Lehnert H.(Bonn / Germany): Ouabain-like factors in human urine: identification of a Na-K-ATPase inhibitor as Vanadium-Diascorbate adduct. Clin Exp Hypert 20: 557-571, 1998
137) Li S, Eim C, Kirch U, Lang RE, Schoner W. (Giessen / Germany): Bovine adrenals and hypothalamus are a major source of proscillaridin A- and ouabain-immunoreactivities. Life Sci 62:1023-33, 1998
138) Qazzaz HM, Valdes R Jr. (Louisville / USA): Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues. Arch Biochem Biophys. 328: 193-200, 1996
139) Doris PA(Houston (Texas) / USA): Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 266: H360- H364, 1994
140) Lewis LK, Tim G.Yandle, John G.Lewis, A.Mark Richards, Grant B.Pidgeon, Risto J.Kaaja & M.Gary Nicholls (Christchurch / Neuseeland) Ouabain is not detectable in human plasma. Hypertension 24: 549-555, 1994
141) Yamada K, A.Goto & M.Omata (Tokio): Adrenocorticotropin-induced hypertension in rats: role of ouabain-like compound. Am J Hypertens 10: 403-408, 1997
142) Komiyama Y, Y.Kimura, N.Nishimura, K.Hara, T.Mori, K.Okuda, M.Munakata, M.Masuda, T.Murakami & H.Takahashi (Osaka / Japan): Vasodepressor effects of exercise are accompanied by reduced circulating ouabainlike immunoreactivity and normalization of nitric oxide synthesis. Clin Exp Hypertens 19: 363-72, 1997
143) Lichtstein D, Michael Steinitz, Irith Gati, Sarah Samuelov, Joseph Deutsch & Joseph Orly (Jerusalem): Biosynthesis of digitalis-like compounds in rat adrenal cells. Life Sci 62: 2109-2126, 1998
144) Doris PA, Leigh Ann Jenkins & Douglas M.Stocco: Is Ouabain an authentic endogenous mammalian substance derived from the adrenal ? Hypertension 23: 632-638, 1994
145) Ferrandi M, P.Manunta, S.Balzan, J.M.Hamlyn, G.Bianchi & P.Ferrari (Mailand & Baltimore / USA): Ouabainlike factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 30: 886, 1997
146) Shaik IM, B.W.Lau, B.A.Siegfried & R.Valdes Jr (Kentucky / USA): Isolation of digoxin-like immunoreactive factors from mammalian adrenal cortex. J Biol Chem 266: 13672-78, 1991
147) Goto A & Yamada K (Tokio): Purification of endogenous digitalis-like factors from normal human urine. Clin Exp Hypertens 20: 551-556, 1998
148) Qazzaz HM, El-Masri MA, Valdes R Jr. (Louisville / Kentucky / USA): Secretion of a lactone-hydrogenated ouabain-like effector of sodium, potassium-adenosine triphosphatase activity by adrenal cells. Endocrinology 41: 3200-9, 2000
149) Lichtstein D, I.Gati, S.Samuelov, D.Berson, Y.Rozenman, L.Landau & J.Deutsch (Jerusalem): Identification of digitalis-like compounds in human cataractous lenses. Eur J Biochem 216: 261-268, 1993
150) AlexeBagrov AY, Olga V.Fedorova, Renata I.Dmitrieva, William N Howald, Ann P. Hunter, Elena A.Kuznetsova, Vladimir M.Shpen (St.Petersburg): Characterization of a urinary bufodienolide Na-K-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 31: 1097-1103, 1998
151) Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, Takahashi H.(Osaka):. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem.38(1):36-45, 2005
152) Graves SW, K.E.Markides & N.K.Hollenberg (Provo / USA): Application of supercritical fluid chromatography to characterize a labile digitalis-like factor. Hypertension 2000, 36(6): 1059-1064
153) Qazzaz HM & Valdes jr. R(Louisville (Kentucky) / USA): Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues. Arch Biochem Biophys 328: 193-200, 1996
154) R.Antolovic, H.Kost, M.Mohadjerani, D.Linder, M.Linder & W.Schoner (Gießen): A specific binding protein for cardiac glycosides exists in bovine serum. J Biol Chem 273: 16259-16264. 1998
155) Schoner W(Gießen): Ouabain, a new steroid hormone of adrenal gland and hypothalamus. Exp Clin Endocrinol Diabetes 108: 449-454, 2000
156) Woolfson RG, Poston L: Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension 17:619-625, 1991 (the study shows the enganced reaction to NO even when the abstract doesn´t cite exactly)
157) Woolfson RG, Nicholas T.Richards & Lucilla Poston (London): Low-concentration ouabain does not inhibit noradrenaline-induced contraction of human resistance arteries. Clin Sci 81: 525-529, 1991
158) Nelissen-Vrancken G, Ju-Feng Wang, Harry A.J.Struijker Boudier, Regien G.Schoemaker, Jos S.F.Smits (Maastricht / Nederlands): Ouabain improves cardiac functionin vivo in rats with heart failure after chronic but not acute treatment. Naunyn-Schmiedebergs Arch Pharmacol 356: 203-209, 1997
159) Wang J, Aldo Tempini, Bruno Schnyder and Jean-Pierre Montani (Fribourg / Schweiz): Regulation of blood pressure during long-term ouabain infusion in Long-Evans rats. Am J Hypertens 12: 423-426, 1999
160) Li M, Allison Martin, Cheng Wen, Steven W.Turner & Lynley K.Lewis, Judith A.Witworth (University of New South Wales / Australien & Christchurch / Neuseeland): Long term ouabain administration does not alter blood pressure in conscious Sprague-Dawley rats. Clin Exp Pharmacol Physiol 22: 919-923, 1995
161) Cargnelli G, Lucia Trevesi, Patrizia Debretto, Sisto Luciani & Sergio Bova (Padua): Effect of long-term ouabain treatment on contractile response of rat aortae. J Cardiovasc Pharmacol 35: 538-542, 2000
162) Manunta P, A.C.Rogowski, B.P.Hamilton, J.M.Hamlyn (Baltimore / USA): Ouabain induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. J Hypertens 12: 549-560, 1994
163) Tamura M, H.Utsunomiya, M.Nakamura & E.J.Landon (Nashville / USA): Effect of dietary glycosides on blood pressure regulation in rats: Can J Physiol Pharmacol 78(7): 548-56, 2000
164) Yuan CM, Paolo Manunta, John M.Hamlyn, Shanwan Chen, Erin Bohen, Jane Yeun, Francis J.Haddy & Motilal B.Pamnani (Bethesda, Washington, Baltimore / USA): Long-term ouabain administration produces hypertension in rats. Hypertension 22: 178-187, 1993
165) in german: Kuschinsky G: Die Verhütung von Erschöpfungszuständen des Herzens. Klin Wschr 24/25 (1947) 502-503
166) personal communication, J.M. Hamlyn to an employee of the manufacturing firm of Strodival®, the oral ouabain medicament, BRAHMS Arzneimittel GmbH, Wiesbaden (nowadays MEDA GmbH ,Wiesbaden), at the 65th birthday of Prof. W. Schoner in Giessen 1999
167). Gottlieb S, A.S.Rogowski, M.Weinberg, C.M.Krichten, B.P.Hamilton & J.M.Hamlyn (Baltimore / USA): Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86: 420, 1992
168) Rossi GP, P.Manunta, J.M.Hamlyn, E.Pavan, R.De Toni, A.Semplicini & A.C.Pessina (Padua / Italy): Immuno-reative endogenous ouabain in primary aldosteronism and essential hypertension. J Hypertens 13: 1181-1191, 1995
169) Manunta P, P.Stella, R.Rivera, D.Ciurlino, D.Cusi, M.Ferrandi, J.M.Hamlyn & G.Bianchi (Milan / Italy)): Left ventricular mass, stroke volume and ouabain-like factor in essential hypertension. Hypertension 34: 450-456, 1999
170) Wang JG, Staessen JA, Messaggio E, Nawrot T, Fagard R, Hamlyn JM, Bianchi G, Manunta P. (Leuven / Belgium): Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 21:1475-81, 2003
171) Lanzani C, Citterio L, Jankaricova M, Sciarrone MT, Barlassina C, Fattori S, Messaggio E, Serio CD, Zagato L, Cusi D, Hamlyn JM, Stella A, Bianchi G, Manunta P. (Milan / Italy & Baltimore / USA): Role of the adducin family genes in human essential hypertension. J Hypertens. 23(3):543-549, 2005
172) Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, Bianchi G; Salt Sensitivity Study Group of the Italian Society of Hypertension.: Plasma ouabain-like factor during acute and chronic changes of sodium balance in essential hypertension. Hypertension 38: 198-203 (2001).
173) de Wardener HE: Ouabain and hypertension. Nephrol Dial Transplant 12: 384-385, 1997 (no abstract available at Pubmed)
174) Buckalew Jr. VM & Gonick HC(Winston-Salem / USA) : Summary of a symposium on natriuretic and digitalis-like factors. Clin Exp Hypertens 20: 481-488, 1998
175) Wechter WJ & Murray Jr. ED: Has the elusive "natriuretic factor" been discovered, and if so, is it an hormone? Exp Nephrol 6: 488-490, 1998
176) Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY. (Baltimore / USA): Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension. Circulation 105:1122-7 (2002)
177) D'Urso G, Frascarelli S, Balzan S, Zucchi R, Montali U: Production of ouabain-like factor in normal and ischemic rat heart. J Cardiovasc Pharmacol 43(5):657-62. 2004
178) Angelis C & Haupert Jr. GT (Rom & Harvard University, Boston / USA): Hypoxia triggers release of an endogenous inhibitor of Na-K-ATPase from midbrain and adrenal. Am J Physiol 274: F182-F188, 1998
179) in german: Rundbriefe der Internationalen Gesellschaft für Infarktbekämpfung, später umbenannt in Gesellschaft für Infarktbekämpfung, weitere Umbenennung in Gesellschaft für Infarktverhütung. Sitz: Schorndorf-Haubersbronn, lendable in public libraries
180) Schaper, W. & Pasyk, S. (Max Planck-Institut Bad Nauheim / Germany): Influence of collateral flow on the ischemic tolerance of the heart following acute and subacute coronary occlusion. Circulation 53 (suppl I) : I-57 – I-62, 1976
181) Khouri, E.M., Gregg, D.E., and Lowensohn, H.S.: Flow in the major branches of the left coronary artery during experimental coronary insufficiency in the unanesthetized dog. Circ. Res. 23: 99-109, 1968(no abstract available at PubMed)
182) Elliot EC et al.: Day-to-day changes in coronary hemodynamics secondary to constriction of circumflex branch of left coronary artery in conscious dogs. Circulation Res 22: 237-250, 1968 (no abstract available at PubMed)
183) Elliot EC et al.: Effect of controlled coronary occlusion on collateral circulation in conscious dogs. Am J Physiol
220: 857-861, 1971 (no abstract available at PubMed)
184) Baroldi, G.: Coronary heart disease: Significance of the morphologic lesions. Am Heart J 85 : 1-5, 1973 (no abstract available at PubMed)
185) Baroldi G (Milan / Italy): From atherosclerotic silent plaque to disrupted and activated plaque: histology versus angiographic, angioscopic and intravascular ultrasound imaging. Int J Cardiol 65 Suppl 1:S3-6, 1998
186) Schachinger V, Zeiher AM (Frankfurt/M. / Germany): Atherosclerosis-associated endothelial dysfunction. Z Kardiol 89 Suppl 9:IX/70-74, 2000
187) Baroldi G, Giuliano G: Ischemic heart disease: clinical and pathological mismatch. Can J Cardiol. Suppl A:248A-254, 1986
188) Mikkelsson J, Eskola M, Nikus K, Pietila K, Karhunen PJ, Niemela K (Tampere / Finland): Fatality of myocardial infarction in relation to the coronary anatomy: role of culprit lesion location. Ann Med 36(6):474-9, 2004
189) Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 12:56-62, 1988
190) Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP (Winston-Salem / USA): Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 78:1157-66, 1988
191) Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HAT: Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation 73: 653-61, 1986
192).Erhardt LR, G.Unge, G.Boman (Stockholm): Formation of coronary arterial thrombi in relation to onset of necrosis in acute myocardial infarction in man. Am Heart J 91: 592-598, 1976
193) Erhardt LR, T.Lundmann & H.Mellstedt (Stockholm): Incorporation of 125 I-labelled fibrinogen into coronary arterial thrombi in acute myocardial infarction in man. Lancet 1: 387-390, 1973 (no abstract available at PubMed)
194) a) Baroldi G, Marzilli M, L'Abbate A, Arbustini E: Coronary occlusion: cause or consequence of acute myocardial infarction? Clin Cardiol 13: 49-54, 1990

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2297957b) Baroldi G (Milan & Rome): Morphological and functional significamce of findings in unstable atherothombotic plaque underlying acute coronary syndromes: a review. International Journal of Cardiology 49 (Suppl.): S 3-S 9, 199 (no abstract available at PubMed)
195) Haft JI, al-Zarka AM (Newark): Comparison of the natural history of irregular and smooth coronary lesions: insights into the pathogenesis, progression, and prognosis of coronary atherosclerosis. Am Heart J 126: 551-61, 1993
196) Neri Serneri GG, Boddi M, Arata L, Rostagno C, Dabizzi P, Coppo M, Bini M, Lazzerini S, Dagianti A, Gensini GF (Florence / Italy): Silent ischemia in unstable angina is related to an altered cardiac norepinephrine handling. Circulation 87: 1928-37, 1993
197) Lange RA & Hillis LD: Use and overuse of angiography and revascularization for acute coronary syndromes. N Engl J Med 338: 1838-9, 1998
198) Baroldi G, Silver MD, Mariani F, Giuliano G (Milan /Italy): Correlation of morphological variables in the coronary atherosclerotic plaque with clinical patterns of ischemic heart disease. Am J Cardiovasc Pathol 2: 159-172, 1988
199) Baroldi G: Diseases of the extramural coronary arteries. In Cardiovascular Pathology (MD Silver ed.), 2nd edn. New York: Churchill Livingstone Inc., 1991; 487-563
200) Sroka K (Hamburg / Germany): On the genesis of myocardial ischemia. Z Kardiol. 2004 Oct;93(10):768-83
201) Bartels GL, Remme WJ, Pillay M, Schonfeld DH, Kruijssen DA (Rotterdam / Netherlands): Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 74:125-30, 1994
202).Cross HR, George K.Radda & Kieran Clarke (Oxford): The role of Na-K-ATPase activity during low flow ischemia in preventing myocardial injury: a [31]P, [23]Na,and [87]Rb NMR spectroscopic study. Magn Reson Med 34: 673-685, 1995
203) Fan THM, Robert P.Frantz, Helen Elam, Susumu Sakamoto & Naokami Imai Chang-Seng Liang (Rochester / USA): Reduction of myocardial Na-K-ATPase activity and ouabain binding sites in heart failure: prevention by nadolol. Am J Physiol 265: H2086-H2093, 1993
204) Hori M, Maruyama Y, Reneman R. S. (Eds): Cardiac Adaptation and Failure, Springer 1994
205) Collins-Nakai RL, Noseworthy D, Lopaschuk GD (Edmonton/ Canada): Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. Am J Physiol. 267: H1862-71, 1994
206) Depre C, Ponchaut S, Deprez J, Maisin L, Hue L (Brussels): Cyclic AMP suppresses the inhibition of glycolysis by alternative oxidizable substrates in the heart. J Clin Invest 101: 390-7, 1998
207) Williamson JR: Metabolic effects of epinephrine in the isolated, perfused rat heart. J Biol Chem. 239: 2721-9, 1964 (no abstract available at PubMed)
208) Messer JV, Levine HJ, Wagman RJ, Gorlin R: Effect ofexercise on cardiac performance in human subjects with coronary artery disease. Circulation. 1963 Sep;28:404-14 (no abstract available at PubMed)
209) Gorlin R: Physiologic studies in coronary atherosclerosis. Fed Proc 1962 Jul-Aug;21(4)Pt 2:93-7 (no abstract available at PubMed)
210) Neill WA: Myocardial hypoxia and anerobic metabolism in coronary heart disease. Am J Cardiol 22: 507-15, 1968 (no abstract available at PubMed)
211) Krasnow N, Neill WA, Messer JV, Gorlin R: Myocardial lactate and pyruvate metabolism. J Clin Invest. 41: 2075-85, 1962 (no abstract available at PubMed)
212) Krasnow N, Gorlin R: Myocardial lactate metabolism in coronary insufficiency. Ann Intern Med 59: 781-7, 1963 (no abstract available at PubMed)
213) Brachfeld N, Scheuer J: Metabolism of glucose by the ischemic dog heart. Am J Physiol 212: 603-6, 1967 (no abstract available at PubMed)
214) Araujo LI, P.Camici, T.J.Spinks, T.Jones & A.Maseri (London): Abnormalities in myocardial metabolism in patients with unstable angina as assessed by positron emission tomography. Cardiovasc Drugs Ther 2: 41-46, 1988
215) Nakano A, Lee JD, Shimizu H, Yonekura Y, Ueda T (Fukui /Japan): Clinical significance of augmented fluorine-18 deoxyglucose uptake in remote normoperfused myocardium in patients with acute coronary syndrome under fasting conditions. J Nucl Cardiol 7: 454-60, 2000.
216) Vanden Hoek TL, Zuohui Shao, Changqing Li, Paul T.Schumacker & Nance B.Becker (Chicago / USA): Mitochondrial electron transport can become a significant source of oxidative injury in cardiomyocytes. J Mol Cell Cardiol 29: 2441-2450, 1997
217) Dhalla NS, Rana M.Temsah & Thomas Netticadan (Winnipeg / Kanada): Role of oxidative stress in cardiovascular diseases. J Hypertension 18: 655-673, 2000
218) Stangl V, Gert Baumann, Karl Stangl & Stephan B.Felix (Berlin & Greifswald / Germany): Negative inotropic mediators released from the heart after myocardial ischemia - reperfusion. Cardiovasc Res 53: 12-30, 2002
219) Spitzer KW, Bridge JH (Salt Lake City / USA): Relationship between intracellular pH and tension development in resting ventricular muscle and myocytes. Am J Physiol 262: C316-27, 1992
220) Harrison SM, Frampton JE, McCall E, Boyett MR, Orchard CH (Leeds / UK): Contraction and intracellular Ca2+, Na+, and H+ during acidosis in rat ventricular myocytes. Am J Physiol. 1992 Feb;262(2 Pt 1):C348-5
221) Baroldi G,: Different morpholiogical types of myocardial cell deyth in man. In: Fleckenstein A, Rona G (ed): Recent advances in studies on cardiac structure and metabolism, Vol. 6. Pathophysiology and morphology of myocardial cell alteration. University Park Press, Baltimore, pp. 383-397, 1975
222) Kawada T, Yamazaki T, Akiyama T, Sato T, Shishido T, Inagaki M, Takaki H, Sugimachi M, Sunagawa K: Differential acetylcholine release mechanisms in the ischemic and non-ischemic myocardium. J Mol Cell Cardiol 32: 405-14, 2000
223) Kawada T, Yamazaki T, Akiyama T, Inagaki M, Shishido T, Zheng C, Yanagiya Y, Sugimachi M, Sunagawa K: Vagosympathetic interactions in ischemia-induced myocardial norepinephrine and acetylcholine release. Am J Physiol Heart Circ Physiol 280: H216-2, 2001
224) Sroka K, Peimann CJ, .Seevers H (Hamburg / Germany): Heart rate variability in myocardial ischemia during daily life. J Electrocardiol 30: 45-56, 1997
225) Pozzati A, Pancaldi LG, Di Pasquale G, Pinelli G, Bugiardini R (Bologna / Italy): Transient sympathovagal imbalance triggers "ischemic" sudden death in patients undergoing electrocardiographic Holter monitoring. J Am Coll Cardiol 17: 847-852, 1996
226) Vardas PE, Kochiadakis GE, Manios EG, Kanoupakis EM, Zouridakis EG, Chlouverakis GI (Iraklion, Crete, Greece): Spectral analysis of heart rate variability before and during episodes of nocturnal ischaemia in patients with extensive coronary artery disease. Eur Heart J 17: 388-393, 1996
227) van Boven AJ, Brouwer J, Crijns HJ, Haaksma J, Lie KI (Groningen / Netherlands) Differential autonomic mechanisms underlying early morning and daytime transient myocardial ischaemia in patients with stable coronary artery disease. Br Heart J 73: 134-138, 1995
228) Goseki Y, Matsubara T, Takahashi N, Takeuchi T, Ibukiyama C (Tokyo): Heart rate variability before the occurrence of silent myocardial ischemia during ambulatory monitoring. Am J Cardiol 73: 845-849, 1994
229) Bigger JT Jr, Hoover CA, Steinman RC, Rolnitzky LM, Fleiss JL and the Multicenter Study of silent myocardial ischemia investigators (N.Y.) : Autonomic nervous system activity during myocardial ischemia in man estimated by power spectral analysis of heart period variability. Am J Cardiol 66: 497-498, 1990 (no abstract available at PubMed)
230) Rosen SD (London): The pathophysiology of cardiac syndrome - a tale of paradigm shifts. Cardiovasc Res 52: 174-177, 2001 (no abstract available at PubMed)
231) Hayano J, Yamada A, Mukai S, Sakakibara Y, Yamada M, Ohte N, Hashimoto T, Fujinami T, Takata K (Nagoya / Japan): Severity of coronary atherosclerosis correlates with the respiratory component of heart rate variability. Am Heart J 121: 1070-9, 1991
232) Nolan J, Flapan AD, Reid J, Neilson JM, Bloomfield P, Ewing DJ (Edinburgh / Scotland): Cardiac parasympathetic activity in severe uncomplicated coronary artery disease. Br Heart J 71: 515-20, 1994
233) Rich MW, Saini JS, Kleiger RE, Carney RM, teVelde A, Freedland KE (St.Louis / USA): Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. Am J Cardiol 62:714-717, 1988
234) Takase B, Kurita A, Noritake M, Uehata A, Maruyama T, Nagayoshi H, Nishioka T, Mizuno K, Nakamura H (Saitama / Japan): Heart rate variability in patients with diabetes mellitus, ischemic heart disease, and congestive heart failure. J Electrocardiol 25:79-88, 1992
235) Kop WJ, Verdino RJ, Gottdiener JS, O'Leary ST, Bairey Merz CN, Krantz DS (Bethesda / USA): Changes in heart rate and heart rate variability before ambulatory ischemic events(1). J Am Coll Cardiol 38: 742-9, 2001
236) Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, Levy D (Osaka / Japan): Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 94: 2850-5, 1996
237) Huang J, Sopher SM, Leatham E, Redwood S, Camm AJ, Kaski JC (London): Heart rate variability depression in patients with unstable angina. Am Heart J 130: 772-9, 1995
238) Bigger JT Jr, Kleiger RE, Fleiss JL, Rolnitzky LM, Steinman RC, Miller JP (New York): Components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol 61: 208-15, 1988
239) Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN (New York): Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 85: 164-71, 1992
240) Farrell TG, Odemuyiwa O, Bashir Y, Cripps TR, Malik M, Ward DE, Camm AJ (London): Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. Br Heart J 67: 129-37, 1992
241) Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward DE, Camm AJ (London): Risk
stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. Am Coll Cardiol 18: 687-97, 1991
242) Hartikainen JE, Malik M, Staunton A, Poloniecki J, Camm AJ (London): Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electro-cardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 28: 296-304, 1996
243) Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ (London): Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59: 256-62, 1987
244) Odemuyiwa O, Malik M, Farrell T, Bashir Y, Poloniecki J, Camm J (London): Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 68: 434-9, 1991
245) Zuanetti G, Neilson JM, Latini R, Santoro E, Maggioni AP, Ewing DJ: Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 94: 432-6, 1996
246) Loffelholz K, Pappano AJ: The parasympathetic neuroeffector junction of the heart. Review. Pharmacol Rev 37: 1-24, 1985
247) Fawcett DW, Selby CC: Observations on the fine structure of the turtle atrium. J Biophys Biochem Cytol 4: 63-72, 1958 (no abstract available at PubMed)
248) Reemtsma K, Delgado JP, Creech O Jr.: Transplantation of the homologous canine heart: serial studies of myocardial blood flow, oxygen consumption, and carbohydrate metabolism. Surgery 47: 292-300, 1960 (no abstract available at PubMed)
249) Jesseph JE, Herron PW, Winterscheid LC, VettoRR, Merendino KA: Carbohydrate metabolism of the isolated perfushed dog heart. Surg Forum. 1957;8:290-4 (no abstract available at PubMed)
250) Winterscheid LC, Bruce RA, Blumberg JB, Merendino KA. Effects of isoproterenol on carbohydrate metabolism of isolated canine heart. Circ Res. 1963 Jan;12:76-84 (no abstract available at PubMed)
251) Sroka K: Herzinfarkt vermeiden. Psychosozial, Gießen (Germany), 2002
252) Horsten M, Ericson M, Perski A, Wamala SP, Schenck-Gustafsson K, Orth-Gomer K (Stockholm): Psychosocial factors and heart rate variability in healthy women. Psychosom Med 61: 49-57, 1999
253) Harrison LL, Leeper JD, Yoon M (Tuscaloosa / USA): Effects of early parent touch on preterm infants' heart rates and arterial oxygen saturation levels. J Adv Nurs. 1990 Aug;15(8):877-85
254) Brody S, Veit R, Rau H (Tübingen / Germany): A preliminary report relating frequency of vaginal intercourse to heart rate variability, Valsalva ratio, blood pressure, and cohabitation status. Biol Psychol 52: 251-7, 2000
255) McCraty R, Atkinson M, Tiller WA, Rein G, Watkins AD (Boulder Creek / USA)): The effects of emotions on short-term power spectrum analysis of heart rate variability. Am J Cardiol 76: 1089-93, 1995 Erratum in: Am J Cardiol 77: 330, 1996
256) Bundgaard H, K.Kjeldsen, K.S.Krabbe, G.Van Hall, L.Simonsen, J.Qvist, C.M.Hansen, K.Moeller, L.Fonsmark, P.L.Madsen & B.K.Pedersen (Kopenhagen): Endotoxemia stimulates skeletal muscle Na,K-ATPase and increases blood lactate level under aerobic conditions in humans. Am J Physiol 284(3): H1028-H1034, 2003
257) Gore DC, Farook Jahoor, Jaqueline M.Hibbert & Eric J.DeMaria (Richmond & Houston / USA): Lactic Acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 224: 97-102, 1996
258) Hotchkiss RS, Irene E.Karl (St.Louis / USA): Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. J Am Med Assoc 267: 1503-1510, 1992
259) Hotchkiss RS, Sheng-Kwei Song, Jeffrey J.Neil, Robert D.Chen, Jill K.Manchester, Irene E.Karl, Oliver H.Lowry & Joseph J.H.Ackerman (St.Louis / USA): Sepsis does not impair tricarboxylic acid cycle in the heart. Am J Physiol 260: C50-C57, 1991
260) Hotchkiss RS, Robert S.Rust, Carmen S.Dence, Todd H.Wasserman, Sheng-Kwei Song, Dah-Ren Hwang, Irene E. Karl & Michael J.Welch (St.Louis / USA): Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker (18F)fluoromisonidazole. Am J Physiol 261: R965-R972, 1991
261) Keul J, Keppler D, Doll E /Freiburg / Germany): Lactate-pyruvate ratio and its relation to oxygen pressure in arterial, coronarvenous and femoralvenous blood. Arch Int Physiol Biochim 75: 573-8, 1967
(no abstract available at PubMed)
262) Keul J, E Doll, D Keppler, J S Skinner: Energy Metabolism of Human Muscle. Karger, Basel 1972
263) Cerretelli P, Samaja M: Acid-base balance at exercise in normoxia and in chronic hypoxia. Revisiting the "lactate paradox". Eur J Appl Physiol 90: 431-48, 2003
264) Wendt L, Wendt T, Wendt A (Frankfurt on the Main / Germany): Protein transport and protein storage in etiology and pathogenesis of arteriosclerosis. Z Ernahrungswiss 20: 1-43, 1981 (No abstract available at Pubmed)
265) Dong XH, Komiyama Y, Nishimura N, Masuda M, Takahashi H (Osaka / Japan): Nanomolar level of ouabain increases intracellular calcium to produce nitric oxide in rat aortic endothelial cells. Clin Exp Pharmacol Physiol. 2004 May-Jun;31(5-6):276-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15191398&query_hl=6
266) W. Rothmund: Kurzfibel der kardiologischen Praxis. Kardiologie Verlag Hauersbronn-Schorndorf 1971
267) E.Edens: Digitalis-Fibel für den Arzt. Verlag Julius Springer, Berlin 1941, page 21.
268) F.Hildebrandt: Über die Kumulation der Digitalisglykoside am Meerschweinchen-Herzen, Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 204: 662-673, 1947


Rolf-Jürgen Petry e-mail: strophanthin@web.de
Dahldorfer Str. 37
D 27442 Gnarrenburg
Tel. 0160 - 98 208 701

User Status

Du bist nicht angemeldet.

Aktuelle Beiträge

Ouabain - the optimal...
Extracts from the book “Ouabain - the possible...
Rolf-Jürgen Petry - 24. Sep, 19:24
Without doubt ouabain...
Without doubt ouabain (g-strophanthin) could be the...
Rolf-Jürgen Petry - 16. Jul, 00:18
100) McCarter FD, James...
100) McCarter FD, James JH, Luchette FA, Wang L, Friend...
Rolf-Jürgen Petry - 27. Dez, 20:20





Online seit 4344 Tagen
Zuletzt aktualisiert: 4. Feb, 11:14


vi knallgrau GmbH

powered by Antville powered by Helma

xml version of this page

twoday.net AGB

Weblog abonnieren